=== PAGE 37 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Here is the extracted text content from the PDF page, preserving its original layout and structure:

(Blue banner with a pink vertical strip on the left)
Important Safety Information (Cont.)

WARNINGS AND PRECAUTIONS

Thromboembolic Disorders and Other Vascular Problems: Stop NEXTSTELLIS if a thrombotic or
thromboembolic event occurs. Start no earlier than 4 weeks after delivery. Consider all cardiovascular risk
factors before initiating in any female, particularly in the presence of multiple risk factors.

Hyperkalemia: Check serum potassium concentration during the first NEXTSTELLIS treatment cycle in females
on long-term treatment with medications that may increase serum potassium concentration.

Hypertension: Monitor blood pressure periodically and stop use if blood pressure rises significantly.

Migraine: Discontinue if new, recurrent, persistent, or severe migraines occur.

Hormonally Sensitive Malignancy: Discontinue NEXTSTELLIS if a hormonally sensitive malignancy is diagnosed.

Liver Disease: Withhold or permanently discontinue for persistent or significant elevation of liver enzymes.

(Black circle logo with "mayne pharma" in white text inside)
mayne pharma

36                                                                           Full Prescribing Information is available at www.Nextstellis.com
